Kite Pharma (KITE) Will Make Late-Breaking Presentation of KTE-C19 ZUMA-1 Trial Data at ASH 2016
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Kite Pharma, Inc. (Nasdaq: KITE) announced that data from the interim analysis of the pivotal ZUMA-1 trial of KTE-C19 in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) have been accepted as an oral late-breaking presentation at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego, CA, on December 6, 2016. The abstract was one of only six accepted in this category and will be included in the December 1 online issue of Blood.
“Outcomes for patients with aggressive NHL depend on whether their disease is sensitive to chemotherapy. The ZUMA-1 study was designed to support registration of KTE-C19 by enrolling a well-defined chemorefractory patient population,” said Jeff Wiezorek, M.D., Senior Vice President of Clinical Development of Kite. “We are pleased with the outcome of the study to date and thank the patients and investigators for their participation in the first positive pivotal study in CAR-T therapy.”
The abstract, titled “KTE-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1,” will be presented by Sattva S. Neelapu, M.D., Associate Professor at the University of Texas MD Anderson Cancer Center, Houston, TX.
Session Name: Late-Breaking Abstracts SessionSession Date: Tuesday, December 6, 2016Session Time: 7:30 AM - 9:00 AM PTPresentation Time: 8:45 AM PTRoom: San Diego Convention Center, Hall AB
This oral presentation will feature interim results from the ZUMA-1 Phase 2 trial. In September 2016, Kite announced ZUMA-1 positive interim topline results (objective response rate 79 percent; complete remission rate 52 percent) from 62 patients with 3 months of follow-up in both Cohort 1 and Cohort 2. Cohort 1 included patients with DLBCL, and Cohort 2 enrolled patients with transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Details of data available at the time of interim analysis, including 93 patients who had the opportunity to be followed for one month, will be presented in the late-breaker presentation on December 6, 2016. Cohort 2 data will be covered in a separate oral presentation on December 5, 2016: Abstract #998, A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1, https://ash.confex.com/ash/2016/webprogram/Paper94812.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Load Factor Rose 0.9 Points in November 2016
- Kite Pharma Appoints Jian Irish, PhD as Senior Vice President of Supply Chain
- NeuroDerm (NDRM) Announces Top-Line Data from ND0701 PK Trial; Results Comparable to Reference Drug
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!